Sugi Predict

Sugi Predict / Compounds / SCHEMBL3361567

SCHEMBL3361567

SCHEMBL3361567

O=c1cc(N2CCOCC2)oc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKDC P78527 19/20 1.00
▸ ACE P12821 1/20 1.00
▸ ECE1 P42892 1/20 1.00
▸ XRCC6 P12956 1/20 0.72
▸ XRCC5 P13010 1/20 0.72
▸ PIK3R1 P27986 2/20 0.64
▸ PIK3CA P42336 2/20 0.64
▸ MTOR P42345 2/20 0.64
▸ TDP1 Q9NUW8 1/20 0.64
▸ KDM4E B2RXH2 2/20 0.61
▸ ALDH1A1 P00352 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ PIK3CD O00329 1/20 0.61
▸ PDE2A O00408 1/20 0.61
▸ PIK3C2A O00443 1/20 0.61
▸ PIK3R2 O00459 1/20 0.61
▸ PIK3C2B O00750 1/20 0.61
▸ BRD4 O60885 1/20 0.61
▸ PDE5A O76074 1/20 0.61
▸ TP53 P04637 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30218216 1.00 PRKDC (1.00) PRKDCACEECE1XRCC6XRCC5
SCHEMBL31035740 0.86 PRKDC (0.75) PRKDCACEECE1XRCC6XRCC5
SCHEMBL3536668 0.84 PRKDC (1.00) PRKDCACEECE1XRCC6XRCC5
SCHEMBL31060252 0.84 PRKDC (1.00) PRKDCACEECE1XRCC6XRCC5
SCHEMBL3542251 0.83 PRKDC (1.00) PRKDCACEECE1XRCC6XRCC5
SCHEMBL13435723 0.83 PRKDC (0.81) PRKDCACEECE1XRCC6XRCC5
SCHEMBL31060404 0.83 PRKDC (1.00) PRKDCACEECE1XRCC6XRCC5
SCHEMBL25246006 0.83 PRKDC (0.71) PRKDCACEECE1XRCC6XRCC5
SCHEMBL5476610 0.83 PRKDC (0.71) PRKDCACEECE1XRCC6XRCC5
SCHEMBL7325705 0.83 PRKDC (0.71) PRKDCACEECE1XRCC6XRCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5703075-A Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones PHARMACIA & UPJOHN COMPANY (US) 1997-12-30 — — US claimed
EP-0525123-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES. UPJOHN CO (US) 1993-02-03 — — EP claimed
EP-0459983-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES PHARMACIA & UPJOHN COMPANY (US) 1991-12-11 — — EP claimed
WO-1990006921-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1990-06-28 — — WO claimed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 — — EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 — — WO disclosed
CN-117615763-A Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof 健道生物医药有限公司 2024-02-27 — — CN disclosed
EP-4284375-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Geode Therapeutics Inc. (US) 2023-12-06 — — EP disclosed
WO-2022164812-A1 PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF GEODE THERAPEUTICS INC. (US) 2022-08-04 — — WO disclosed
CN-101506211-B Kinase antagonists UNIV CALIFORNIA 2013-05-22 — — CN disclosed
US-20120129881-A1 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER BURKE GREGORY (US) 2012-05-24 — — US disclosed
US-20100130597-A1 DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) 2010-05-27 — — US disclosed
EP-1417196-A1 DNA-PK INHIBITORS Cancer Research Technology Limited (GB) 2004-05-12 — — EP disclosed
WO-2003024949-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2003-03-27 — — WO disclosed
US-5703075-A Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones PHARMACIA & UPJOHN COMPANY (US) 1997-12-30 — — US disclosed
EP-0525123-B1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES UPJOHN CO (US) 1997-09-17 — — EP disclosed
EP-0525123-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES. UPJOHN CO (US) 1993-02-03 — — EP disclosed
WO-1991019707-A2 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1991-12-26 — — WO disclosed
EP-0459983-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES PHARMACIA & UPJOHN COMPANY (US) 1991-12-11 — — EP disclosed
WO-1990006921-A1 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES THE UPJOHN COMPANY (US) 1990-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130597-A1 DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION PRKAB1, PRKAG1, PRKAB2 PRKDC 81/4885ACE 4758/4885ECE1 3385/4885
US-20120129881-A1 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER MTOR, CDK4, MAPKAP1 PRKDC 840/4885ACE 4230/4885ECE1 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.